Healthcare / Diagnostics & ResearchWarsaw
$30.95
+0.35 (+1.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $45.4M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$568M
P/E
N/A
•EV/EBITDA
11.4x
↓ROE
0.3%
↓Gross Margin
80.6%
↑Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.3%
FCF CAGR
—
FCF margin
18.2%
FCF / Net income
81.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $364.2M · net income $813000.0 · FCF $66.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $364.2M | $364.2M | $342.0M | $346.7M | $360.7M |
| Net Income | $813000.00 | $813000.00 | $-6.1M | $69.9M | $30.3M |
| EBITDA | $62.7M | $62.7M | $55.3M | $123.5M | $76.1M |
| EPS | — | — | -0.30 | 3.80 | 1.70 |
| Gross Margin | 80.6% | 80.6% | 78.3% | 79.5% | 81.1% |
| Operating Margin | 3.4% | 3.4% | -0.1% | 4.8% | 11.1% |
| Net Margin | 0.2% | 0.2% | -1.8% | 20.2% | 8.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.68 | 0.69 | 0.81 |
| Current Ratio | 1.00 | 1.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $66.1M | $66.1M | $45.4M | $5.0M | $-26.2M |
| Returns | |||||
| ROE | 0.3% | 0.3% | -1.9% | 21.4% | 11.6% |
| Valuation | |||||
| P/E | — | — | — | 15.45 | 48.53 |
| EV/EBITDA | 11.39 | 11.39 | 20.04 | 10.12 | 21.72 |
| P/B | 1.77 | 1.77 | 2.83 | 3.29 | 5.78 |
| Growth & Yield | |||||
| Revenue Growth | 6.5% | 6.5% | -1.4% | -3.9% | — |
| EPS Growth | — | — | -107.9% | 123.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.30 → n/d
Residual
-9.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.